Enhanced and Sustained IOP reduction with MINIject

Show Description +

Iqbal Ike K. Ahmed, MD, FRCSC, discusses the advantages of MINIject (iSTAR Medical) - a novel, ab interno, micro-invasive glaucoma surgery (MIGS) device. He explains how the STAR® material minimizes fibrosis and sustains the efficacy of the implant. Michel Vanbrabant, CEO of iSTAR Medical, describes the unique structure of MINIject, and Steven Vold, MD, shares his experience with MINIject in the first-in-human trial.

Posted: 9/13/2018

Up Next


Consider the Supraciliary Space With MINIject

Joseph F. Panarelli, MD; and I. Paul Singh, MD

Question and Answer: MINIject Supraciliary MIGS Device

Joseph F. Panarelli, MD; Leon Au, BSc, MBBS, FRCOphth; and Tim Schultz, MD, PhD, FEBO

STAR-GLOBAL 3-Year Results

I. Paul Singh, MD

Q&A: MINIject Supraciliary MIGS Device

Steven R. Sarkisian Jr, MD; Karsten Klabe, MD; Faisal Ahmed, MD; and I. Paul Singh, MD

Full Webinar: An Eye-Opening Update on MIGS

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

European STAR-II Trial Results at One Year

Julián García-Feijoó, MD, PhD

Webinar Part 1: Where Do We Stand With MIGS?

Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 2: How Can We Leverage the Power of the Supraciliary Space?

Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD, Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 3: The MINIject™ Next-Generation Supraciliary Device

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

Webinar Part 6: Clinical Trial Results Q&A and Next Steps

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

Enhanced and Sustained IOP reduction with MINIject

Iqbal Ike K. Ahmed, MD, FRCSC, Michel Vanbrabant, Steven Vold, MD

Enhanced and Sustained IOP reduction with MINIject

Iqbal Ike K. Ahmed, MD, FRCSC, discusses the advantages of MINIject (iSTAR Medical) - a novel, ab interno, micro-invasive glaucoma surgery (MIGS) device. He explains how the STAR® material minimizes fibrosis and sustains the efficacy of the implant. Michel Vanbrabant, CEO of iSTAR Medical, describes the unique structure of MINIject, and Steven Vold, MD, shares his experience with MINIject in the first-in-human trial.

Posted: 9/13/2018

About iSTAR Medical

Visit us online: istarmed.com

Follow iSTAR Medical